Registry of Patients Treated With Plerixafor (MozobilĀ®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bone Marrow / Autologous Transplants
Intervention: Plerixafor (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Genzyme, a Sanofi Company Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Genzyme, a Sanofi Company
Summary
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor
prescription modalities in France, over a 13-month period in order to address the health
authorities' request.
Clinical Details
Official title: Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study
Study design: Time Perspective: Prospective
Primary outcome: The characteristics of the patients who received treatmentDosage of treatment Number of CD34+ cells collected following treatment Number of patients with the existence of one or more predictive factors of poor mobilisation Duration of treatment Associated treatments
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients treated with Plerixafor for autologous transplantation between November 2011
and November 2012
- Patients who have been informed and who have given their written consent for the
access to their medical file
Exclusion Criteria:
- Patients already included in a Plerixafor ongoing clinical trial.
Locations and Contacts
Marseille, France
Additional Information
Starting date: December 2011
Last updated: March 19, 2015
|